Security key
98422T100
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)
CUSIP: 98422T100
Q1 2023 13F Holders as of 31 Mar 2023
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 16,072,057
- Total 13F value
- $50,979,505
- Share change
- +145,544
- SEC-reported price per share
- $3.17
- Number of holders
- 32
- Value change
- +$461,644
- Number of buys
- 10
- Number of sells
- 3
- Shares outstanding
- 6,426,426
Holder snapshot
6 signals
Security identity
1 source field
Report period
Q1 2023
Institutions
32
Top holders
10
XLO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2023
Previous quarter: Q4 2022
Xilio Therapeutics, Inc. SEC filings
Xilio Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98422T100
Recent filing periods:
Ownership snapshot
Top reported holders of XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Bain Capital Life Science...
Disclosed value leader
Bain Capital Life Science...
Comparable rows
15/15
Latest evidence
31 Dec 2022
13F
3/4/5
Lead comparable stake: 44%
Showing 1-6 of 15 holder rows.
Quick read
Bain Capital Life Sciences Investors, LLC leads the comparable SEC ownership view at 44%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
Bain Capital Life Sciences Invest...
44%
Atlas Venture Life Science Adviso...
43%
Octagon Capital Advisors LP
38%
FMR LLC
30%
RiverVest Venture Management LLC
22%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC |
13F
3/4/5
Company · 10%+ Owner
|
44%
|
$7,547,000
2,805,413 shares
|
— | 31 Dec 2022 |
| Atlas Venture Life Science Advisors, LLC |
13F
Company
|
43%
|
$7,422,635
2,759,344 shares
|
— | 31 Dec 2022 |
| Octagon Capital Advisors LP |
13F
Company
|
38%
|
$6,523,250
2,425,000 shares
|
— | 31 Dec 2022 |
| FMR LLC |
13F
3/4/5
Company · Other*
|
30%
|
$5,131,635
1,907,671 shares
|
— | 31 Dec 2022 |
| RiverVest Venture Management LLC |
13F
Company
|
22%
|
$3,877,484
1,441,444 shares
|
— | 31 Dec 2022 |
| Rock Springs Capital Management LP |
13F
3/4/5
Company · 10%+ Owner
|
21%
|
$3,666,142
1,362,878 shares
|
— | 31 Dec 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
32
Shares
16,072,057
Rows available
32
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2023 vs Q4 2022 Across Filers
Q4 2022 holders
28
Q1 2023 holders
32
Holder diff
4
| Investor | Q4 2022 Shares | Q1 2023 Shares | Share Diff | Share Chg % | Q4 2022 value | Q1 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend